Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ganetespib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 known ✓ | P08238 | 20/20 | 1.00 |
| ▸ | HSP90AA1 known ✓ | P07900 | 18/20 | 1.00 |
| ▸ | HSP90B1 | P14625 | 1/20 | 1.00 |
| ▸ | TRAP1 | Q12931 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganetespib SCHEMBL29352120 | 1.00 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| Ganetespib SCHEMBL29376128 | 1.00 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL501479 | 0.91 | HSP90AB1 (0.82) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL9924656 | 0.89 | HSP90AB1 (0.81) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL500866 | 0.89 | HSP90AB1 (0.81) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4566976 | 0.89 | HSP90AB1 (0.79) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4566979 | 0.89 | HSP90AB1 (0.79) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL25602985 | 0.88 | HSP90AB1 (0.78) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL419168 | 0.88 | HSP90AB1 (0.81) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL421109 | 0.88 | HSP90AB1 (0.78) | HSP90AB1HSP90AA1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250160275-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-22 | — | — | US | claimed |
| WO-2023164606-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2016073669-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR INHIBITORS | VUKOVIC VOJO (US) | 2016-05-12 | — | — | WO | claimed |
| WO-2014018862-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A HEAT SHOCK PROTEIN INHIBITOR AND A|PURINE DE NOVO SYNTHESIS INHIBITOR FOR TREATING RHEUMATOID ARTHRITIS OR CANCER | CORNING INCORPORATED (US) | 2014-01-30 | — | — | WO | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| CN-120136941-A | Anti-aging composition and application thereof | 鲁贝多生命科学公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| WO-2007139960-A2 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139952-A2 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | HSP90AB1 303/4885HSP90AA1 392/4885HSP90B1 637/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | HSP90AB1 233/4885HSP90AA1 291/4885HSP90B1 593/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | HSP90AB1 1029/4885HSP90AA1 1729/4885HSP90B1 172/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AB1 1/4885HSP90AA1 4/4885HSP90B1 3/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | HSP90AB1 1053/4885HSP90AA1 1857/4885HSP90B1 138/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | HSP90AB1 1029/4885HSP90AA1 1729/4885HSP90B1 172/4885 |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | HSP90AB1, HSP90B1, CDC37 | HSP90AB1 1/4885HSP90AA1 4/4885HSP90B1 2/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 7/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | HSP90AB1 1053/4885HSP90AA1 1857/4885HSP90B1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.